Cathie Wood, the founder and CEO of ARK Invest, made just three stock purchases last week as markets fell for the fourth straight week. The three major market indexes all moved lower during that period.
Wood typically buys more aggressively during market pullbacks, so the limited activity stood out to investors.
The three stocks she added to were Figma, Arcturus Therapeutics, and 10x Genomics. At the same time, ARK sold shares in several companies, including Circle Internet Group, a crypto-related stock.
Figma is a cloud-based design platform used for websites, apps, and digital products. ARK bought 337,381 shares of Figma on March 20 across its ARKK and ARKW ETFs, totaling $8,171,367.
Figma, Inc., FIG
The stock has fallen 83% from its peak last summer, after more than quadrupling from its IPO price of $33. Despite the sharp decline, Figma reported 40% revenue growth in its most recent quarter, up from 38% the previous quarter.
Its net dollar-retention rate hit 136%, meaning existing customers spent 36% more on the platform compared to a year earlier. That is the strongest reading on that metric in two years.
Analysts expect revenue growth to slow to 30% this year and 20% next year. Figma has not reported strong profitability, which has weighed on the stock.
On the crypto side, ARK sold 45,998 shares of Circle Internet Group across ARKK and ARKW, totaling $5,902,923. ARK had been reducing its Circle Internet position throughout the week.
Circle Internet is a crypto-linked company known for its role in the USD Coin stablecoin ecosystem.
ARK also sold 19,206 shares of Teradyne for $5,807,894, along with 103,379 shares of Bullish for $4,093,808 and 9,621 shares of Guardant Health for $857,038. ARK sold 182,353 shares of Butterfly Network for $723,941.
Arcturus Therapeutics uses messenger RNA technology to develop treatments for rare respiratory and liver diseases. ARK bought shares in Arcturus on three of the five trading days last week, most recently purchasing 22,773 shares on Friday for $153,034 through its ARKG ETF.
Revenue at Arcturus has fallen sharply for three straight years and is expected to drop further in 2026. However, the company recently extended its cash runway to at least the second quarter of 2028.
10x Genomics makes life sciences tools, including its Chromium platform for single-cell genomic analysis. ARK bought 192,658 shares last week across ARKK and ARKG for $3,541,054.
The company went public at $38 per share and now trades around half that price. It has never turned a profit, and its own 2026 guidance points to a revenue decline when including licensing income from patent settlements last year.
The post Cathie Wood Makes Just 3 Stock Buys Last Week — Here’s What She Chose appeared first on CoinCentral.
![Tracking a double three Elliott Wave pattern [Video]](https://i2.wp.com/editorial.fxsstatic.com/images/i/Equity-Index_DJI-2_Medium.jpg)

